7/102 sources · 2 publishersUpdated Oct 8, 21:38 UTC
Korro doses initial ANCHOR trial cohort for KRRO-121
Korro Bio has begun its ANCHOR Phase 1/2 program for KRRO-121, dosing an initial group of healthy volunteers with 2mg/kg. The RNA-editing candidate is being studied for hyperammonemia in people with urea cycle disorders and hepatic encephalopathy. Korro plans to begin treating urea cycle disorder patients during H1 2027 and expects an interim update during H2 2027.
Why it matters
The milestone moves KRRO-121 from preclinical work into human testing. Korro says the initial portion is designed to establish safety, tolerability and pharmacokinetics before the patient study evaluates clinical activity.
Key facts
- 1Korro reported that the initial healthy-volunteer cohort received a single 2mg/kg administration of KRRO-121. sec.gov
- 2The ANCHOR program's first section can enroll up to 50 healthy volunteers, while its patient section can include up to 15 people with urea cycle disorders. sec.gov
- 3The single-ascending-dose portion began in September 2026 and is planned for up to 30 healthy volunteers in up to five cohorts. sec.gov
- 4Korro expects patient dosing to begin in H1 2027 and plans an interim clinical update in H2 2027. sec.gov
Open questions
- Clinical safety, pharmacokinetic and activity results from ANCHOR have not yet been reported.
- The patient-study component remains subject to regulatory approval.
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.